Access Vascular, a Billerica, MA-based company addressing the vascular access complications via a biomaterial platform, raised $22M in Series C funding.
Backers included a consortium of new and existing investors.
The company intends to use the funds for:
- substantial production capacity increase of MIMIX™ hydrophilic biomaterial vascular access devices,
- further research into the potential for MIMIX to lower catheter infection rates, and
- expansion of product portfolio.
Led by James Biggin, Founder and CEO, Access Vascular was founded to address the common complications of intravenous therapy: infection, thrombosis, and phlebitis. Taking a different approach to thrombus reduction, the company manufactures intravenous catheters from a proprietary hydrophilic material. Engineered to mimic the body’s natural chemistry, its catheters are designed to evade the foreign body response and the complications that come with it. Its FDA-cleared products are HydroPICC® and HydroMID®.
FinSMEs
31/10/2023